Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20338753 | 1.00 | FAAH (0.35) | FAAHHDAC1HDAC2HDAC6ALDH1A1 | |
| SCHEMBL20338800 | 0.92 | HDAC6 (0.31) | FAAHHDAC6 | |
| SCHEMBL20338802 | 0.92 | HDAC6 (0.31) | FAAHHDAC6 | |
| SCHEMBL25637462 | 0.77 | CA14 (0.41) | HDAC1HDAC2HDAC6ALDH1A1 | |
| SCHEMBL13007474 | 0.76 | TDP1 (0.37) | HDAC1HDAC2HDAC6 | |
| SCHEMBL21685040 | 0.76 | TDP1 (0.37) | HDAC1HDAC2HDAC6 | |
| SCHEMBL17614515 | 0.76 | CA2 (0.40) | HDAC1HDAC2HDAC6 | |
| SCHEMBL17364213 | 0.75 | HDAC6 (0.33) | HDAC1HDAC2HDAC6 | |
| SCHEMBL17369175 | 0.75 | HDAC6 (0.33) | HDAC1HDAC2HDAC6 | |
| SCHEMBL17309877 | 0.75 | TDP1 (0.39) | HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3405477-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-06-07 | — | — | EP | disclosed |
| US-11072634-B2 | Inhibitors of transglutaminases | ZEDIRA GMBH (DE) | 2021-07-27 | — | — | US | disclosed |
| US-20190322700-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2019-10-24 | — | — | US | disclosed |
| EP-3405477-A1 | INHIBITORS OF TRANSGLUTAMINASES | Zedira GmbH (DE) | 2018-11-28 | — | — | EP | disclosed |
| WO-2018122419-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2018-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322700-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | FAAH 1023/4885HDAC1 876/4885HDAC2 1031/4885 |
| US-11072634-B2 | Inhibitors of transglutaminases | TGM2, TGM3, TGM1 | FAAH 1023/4885HDAC1 876/4885HDAC2 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.